About 22nd Century Group (NYSEAMERICAN:XXII)
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
Industry, Sector and Symbol
Industry Environmental Biotechnology
SymbolNYSEAMERICAN:XXIIPrevious Symbol: AMEX:XXII
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-57.55%
Return on Assets-49.40%
Frequently Asked Questions for 22nd Century Group (NYSEAMERICAN:XXII)
What is 22nd Century Group's stock symbol?
22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."
How were 22nd Century Group's earnings last quarter?
22nd Century Group Inc (NYSEAMERICAN:XXII) announced its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The biotechnology company had revenue of $4.53 million for the quarter, compared to the consensus estimate of $5.09 million. 22nd Century Group had a negative net margin of 86.10% and a negative return on equity of 57.55%. The firm's revenue for the quarter was up 46.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.03) EPS. View 22nd Century Group's Earnings History.
Where is 22nd Century Group's stock going? Where will 22nd Century Group's stock price be in 2017?
1 analysts have issued twelve-month price targets for 22nd Century Group's shares. Their forecasts range from $11.50 to $11.50. On average, they expect 22nd Century Group's stock price to reach $11.50 in the next twelve months. View Analyst Ratings for 22nd Century Group.
What are Wall Street analysts saying about 22nd Century Group stock?
Here are some recent quotes from research analysts about 22nd Century Group stock:
- 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (10/18/2017)
- 2. Chardan Capital analysts commented, "We expect 22nd Century to report Q4 results this week. Our revenue estimate for the quarter is $3.1 million, equivalent to Q3 results. For the full year this results in revenue of $12 million. We expect the company on its earnings call to focus on recent communications with the FDA regarding its PMTA (Premarket Tobacco Product Applications), the MRTP (Modified Risk Tobacco Product) applications and a path forward for X-22. Earlier this month the FDA granted a guidance meeting to discuss X-22 and the ways 22nd Century could attempt to win approval for X-22 as a prescription-based aid for smoking cessation. The company has also received written feedback on the MRTP application for Brand A, the company's very low nicotine (VLN) cigarette. As we progress through the year we expect additional milestones to be reached on 22nd Century's attempt to use its proprietary technology to create VLN products for the smoking cessation market." (3/7/2017)
Are investors shorting 22nd Century Group?
22nd Century Group saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,677,128 shares, a decrease of 2.9% from the October 13th total of 9,966,801 shares. Based on an average daily trading volume, of 4,425,009 shares, the short-interest ratio is currently 2.2 days. Approximately 9.1% of the shares of the stock are short sold.
Who are some of 22nd Century Group's key competitors?
Some companies that are related to 22nd Century Group include Taseko Mines Limited (TGB), Transenterix (TRXC), Klondex Mines Ltd (KLDX), Gossan Resources Limited (GSS), Silvercorp Metals (SVM), Sierra Metals (SMTS), Senseonics Holdings (SENS), Gold Standard Ventures Corp (GSV), Consolidated-Tomoka Land (CTO), Protalix Biotherapeutics (PLX), Spark Networks (LOV), Denison Mines Corp (DNN), BioTime (BTX), EnviroStar (EVI), Lilis Energy (LLEX), Bluerock Residential Growth REIT (BRG), Saga Communications (SGA) and IMPAC Mortgage Holdings (IMH).
Who are 22nd Century Group's key executives?
22nd Century Group's management team includes the folowing people:
- Henry Sicignano III, President, Chief Executive Officer, Director (Age 48)
- John T. Brodfuehrer, Chief Financial Officer, Treasurer (Age 58)
- Thomas L. James Esq., Vice President, General Counsel, Secretary (Age 57)
- Paul Rushton Ph.D., Vice President - Plant Biotechnology (Age 53)
- Michael R. Moynihan Ph.D., Vice President - Research & Development (Age 63)
- James W. Cornell, Non-Executive Independent Chairman of the Board (Age 58)
- Nora B. Sullivan, Director (Age 58)
- Joseph Alexander Dunn Ph.D., Independent Director (Age 62)
- Richard M. Sanders, Independent Director (Age 62)
Who owns 22nd Century Group stock?
22nd Century Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.10%), Advisor Group Inc. (0.07%), Bristol Advisors LLC (0.07%), Wells Fargo & Company MN (0.07%) and Steward Partners Investment Advisory LLC (0.03%). Company insiders that own 22nd Century Group stock include John T Brodfuehrer and Michael Robert Moynihan. View Institutional Ownership Trends for 22nd Century Group.
Who bought 22nd Century Group stock? Who is buying 22nd Century Group stock?
22nd Century Group's stock was purchased by a variety of institutional investors in the last quarter, including Bristol Advisors LLC, Wells Fargo & Company MN, Steward Partners Investment Advisory LLC, Bank of New York Mellon Corp and Advisor Group Inc.. View Insider Buying and Selling for 22nd Century Group.
How do I buy 22nd Century Group stock?
Shares of 22nd Century Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 22nd Century Group's stock price today?
One share of 22nd Century Group stock can currently be purchased for approximately $2.36.
How big of a company is 22nd Century Group?
22nd Century Group has a market capitalization of $279.40 million.
How can I contact 22nd Century Group?
22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.
MarketBeat Community Rating for 22nd Century Group (XXII)MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for 22nd Century Group (NYSEAMERICAN:XXII) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$11.50|
Consensus Price Target History for 22nd Century Group (NYSEAMERICAN:XXII)
Analysts' Ratings History for 22nd Century Group (NYSEAMERICAN:XXII)
(Data available from 11/24/2015 forward)
|10/16/2017||Chardan Capital||Boost Price Target||Buy||$3.50 -> $11.50|
Earnings History and Estimates Chart for 22nd Century Group (NYSEAMERICAN:XXII)
Earnings History by Quarter for 22nd Century Group (NYSEAMERICAN XXII)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.02)||($0.03)||$5.09 million||$4.53 million||View||N/A|
|8/4/2015||Q215||($0.02)||($0.02)||$1.30 million||$2.31 million||View||N/A|
Earnings Estimates for 22nd Century Group (NYSEAMERICAN:XXII)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for 22nd Century Group (NYSEAMERICAN:XXII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for 22nd Century Group (NYSEAMERICAN XXII)
Insider Trades by Quarter for 22nd Century Group (NYSEAMERICAN XXII)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/29/2017||Michael Robert Moynihan||VP||Sell||50,000||$2.67||$133,500.00|| |
|7/31/2017||Michael Robert Moynihan||VP||Sell||29,532||$2.00||$59,064.00|| |
|6/8/2017||Michael Robert Moynihan||VP||Sell||20,468||$2.00||$40,936.00|| |
|10/31/2016||Michael Robert Moynihan||VP||Sell||100,000||$1.28||$128,000.00|| |
|3/29/2016||John T Brodfuehrer||CFO||Buy||12,500||$0.77||$9,625.00|| |
|11/3/2015||Michael Robert Moynihan||VP||Sell||50,000||$1.40||$70,000.00|| |
|6/30/2015||Joseph Pandolfino||Director||Sell||91,178||$0.95||$86,619.10|| |
|12/31/2014||Joseph Pandolfino||Director||Sell||105,124||$1.65||$173,454.60|| |
|12/26/2014||Joseph Pandolfino||Director||Sell||41,722||$1.54||$64,251.88|| |
|12/22/2014||Joseph Pandolfino||Director||Sell||52,683||$1.60||$84,292.80|| |
|12/17/2014||Joseph Pandolfino||Director||Sell||75,768||$1.62||$122,744.16|| |
|12/11/2014||Joseph Pandolfino||Director||Sell||67,836||$1.65||$111,929.40|| |
|5/9/2014||Richard M Sanders||Director||Buy||20,000||$2.23||$44,600.00|| |
|4/23/2014||Michael Robert Moynihan||VP||Sell||100,000||$2.44||$244,000.00|| |
|3/12/2014||Joseph Pandolfino||CEO||Sell||95,000||$5.73||$544,350.00|| |
|12/10/2013||Clearwater Partners, Llc||Major Shareholder||Sell||10,000||$1.55||$15,500.00|| |
|12/3/2013||Clearwater Partners, Llc||Major Shareholder||Sell||10,000||$1.35||$13,500.00|| |
|11/19/2013||Clearwater Partners, Llc||Major Shareholder||Sell||30,074||$1.09||$32,780.66|| |
|11/13/2013||Clearwater Partners, Llc||Major Shareholder||Sell||11,826||$0.98||$11,589.48|| |
|11/11/2013||Clearwater Partners, Llc||Major Shareholder||Sell||7,100||$1.03||$7,313.00|| |
|11/7/2013||Clearwater Partners, Llc||Major Shareholder||Sell||9,000||$1.15||$10,350.00|| |
Latest Headlines for 22nd Century Group (NYSEAMERICAN XXII)
22nd Century Group (NYSEAMERICAN XXII) Chart for Friday, November, 24, 2017